CDER Risk Assessment Exercise to Evaluate Potential Risks from the Use of Nanomaterials in Drug Products
Journal Title: The AAPS Journal - Year 2013, Vol 15, Issue 3
Abstract
The Nanotechnology Risk Assessment Working Group in the Center for Drug Evaluation and Research (CDER) within the United States Food and Drug Administration was established to assess the possible impact of nanotechnology on drug products. The group is in the process of performing risk assessment and management exercises. The task of the working group is to identify areas where CDER may need to optimize its review practices and to develop standards to ensure review consistency for drug applications that may involve the application of nanotechnology. The working group already performed risk management exercises evaluating the potential risks from administering nanomaterial active pharmaceutical ingredients (API) or nanomaterial excipients by various routes of administration. This publication outlines the risk assessment and management process used by the working group, using nanomaterial API by the oral route of administration as an example.
Authors and Affiliations
Celia N. Cruz, Katherine M. Tyner, Lydia Velazquez, Kenneth C. Hyams, Abigail Jacobs, Arthur B. Shaw, Wenlei Jiang, Robert Lionberger, Peter Hinderling, Yoon Kong, Paul C. Brown, Tapash Ghosh, Caroline Strasinger, Sandra Suarez-Sharp, Don Henry, Maat Van Uitert, Nakissa Sadrieh, Elaine Morefield
Keywords
Related Articles
- EP ID EP681121
- DOI 10.1208/s12248-013-9466-6
- Views 48
- Downloads 0
Biodegradable intraprostatic doxorubicin implants
Systemic chemotherapy is not effective in the treatment of prostate-confined cancer. We developed biodegradable, doxorubicin-loaded cylinders for intraprostatic implantation and evaluated the feasibility of using regiona...
RGS6 as a Novel Therapeutic Target in CNS Diseases and Cancer
Regulator of G protein signaling (RGS) proteins are gatekeepers regulating the cellular responses induced by G protein-coupled receptor (GPCR)-mediated activation of heterotrimeric G proteins. Specifically, RGS proteins...
Handling Data Below the Limit of Quantification in Mixed Effect Models
The purpose of this study is to investigate the impact of observations below the limit of quantification (BQL) occurring in three distinctly different ways and assess the best method for prevention of bias in parameter e...
Biomarker qualification pilot process at the US Food and Drug Administration
New biomarkers of safety and efficacy are becoming powerful tools in drug development. Their application can be accelerated if a consensus can be reached about their qualification for regulatory applications. This consen...
Headway and Hurdles in the Clinical Development of Dietary Phytochemicals for Cancer Therapy and Prevention: Lessons Learned from Vitamin A Derivatives
Accumulating epidemiologic and preclinical evidence support the pharmacologic use of a variety of dietary chemicals for the prevention and treatment of cancer. However, it will be challenging to translate these findings...